- Peptide Generic API
- Peptide NCEs
Peptide API CMO Market was estimated to be valued US$ XX Mn in 2021 and poised to grow at significant CAGR over 2022-2028. estimated to be valued US$ XX Mn in 2021 and poised to grow at significant CAGR over 2022-2028 due to increase in prevalence of various types of cancers, other chronic disorders. Moreover, rise in number of deaths due to diseases which do not possess complete cure with the conventional anticoccidial drugs, increasing demand for the R&D services by public and private sectors, increasing global geriatric population, and wide range of applications with the peptide API CMO are the major factors that are driving the growth of the global peptide API CMO market over the forecast timeframe.
Fastest Growing Market
Increase in the prevalence of cancer, autoimmune disorders, and other chronic diseases is a key factor drive the global peptide API CMO market. According to World Health Organization 2018, approximately 9.6 Mn death occurred due to cancer around the globe. Moreover, product approval by the FDA for protein and peptide APIs, raise in funding for the R&D activities by public and private sectors are anticipated to propel the global peptide API CMO market over the forecast years.
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.